parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in neutrophils	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	2 Parkinson's papers of 58	0.85
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 12299

P2RY13 in dopamine neurons, braak+0.28 (p 0.472) → +0.10 (p 0.796)receipt 12307
P2RY13 in microglia, braak+0.78 (p 0.013) → +0.02 (p 0.962)receipt 12306

receipt 12307: P2RY13 in dopamine neurons, braak

power: full sample +0.18 (p 0.487, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.11 (p 0.652, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.18 (p 0.476, n 18). could be the mix.
skeptic: leave-one-out range +0.07 to +0.31, sign flips 0; without severely affected donors +0.18 (p 0.487, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for P2RY13 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12306: P2RY13 in microglia, braak

power: full sample +0.43 (p 0.072, n 18), 95% CI -0.04 to +0.75. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.48 (p 0.046, n 18). holds up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.61 (p 0.0075, n 18). not the mix.
skeptic: leave-one-out range +0.36 to +0.59, sign flips 0; without severely affected donors +0.43 (p 0.072, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for P2RY13 in microglia.

case closed: nothing better to follow up.

loading the receipts